Breaking
Friday, June 19, 2026

FDA News Analysis

🇪🇺 EMA

Expert commentary and market intelligence for pharma strategy teams

Showing 1–12 of 17 articles

High impact AnalysisJun 12, 2026

AI in Drug Discovery Examples: What’s Changed Beyond Early Use Cases

FDA · 7 min

Dr. Elena Rossi
High impact AnalysisJun 7, 2026

Federal Court Litigation on Reproductive Health: Rare Disease Implications

FDA · rare disease · 5 min

Dr. Elena Rossi
High impact AnalysisJun 6, 2026

FDA Voucher Program Pause Urged: Rare Disease Policy Analysis

FDA · rare disease · 5 min

Dr. Elena Rossi
High impact AnalysisJun 4, 2026

Kaléo's Initiative on Allergy Awareness: Amplifying Patient Stories

FDA · allergy · 5 min

Dr. Elena Rossi
High impact AnalysisJun 4, 2026

Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026

FDA · 5 min

Dr. Elena Rossi
High impact AnalysisJun 3, 2026

Tracy Beth Høeg's Departure: Implications for Pharma BD and Regulatory Teams

FDA · 6 min

Dr. Elena Rossi
High impact AnalysisJun 3, 2026

AbbVie Plans Layoffs: Implications for the Pharma Industry

FDA · 6 min

Dr. Elena Rossi
High impact AnalysisJun 2, 2026

Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission

FDA · 9 min

Dr. Elena Rossi
High impact AnalysisJun 2, 2026

ASCO26: AstraZeneca's Camizestrant Data Aims to Sway FDA Approval

FDA · 8 min

Dr. Elena Rossi
High impact AnalysisJun 2, 2026

OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation

FDA · osteosarcoma · 8 min

Dr. Elena Rossi
High impact AnalysisJun 2, 2026

FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC

FDA · NMIBC · 8 min

Dr. Elena Rossi
Critical impact AnalysisJun 2, 2026

ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles

FDA · bladder cancer · 9 min

Dr. Elena Rossi